newsfilter
← Latest News
Business Wire·

Vistagen to Participate in Stifel Healthcare Conference 2025

  • Vistagen (NASDAQ: VTGN) CEO Shawn Singh will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. Eastern Time.
  • The company will host one-on-one meetings during the conference.
  • A live webcast will be available on the "Events" page under "Investors" on www.Vistagen.com, with a replay archived post-event.
  • Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing intranasal product candidates called pherines.
  • Pherines bind to peripheral receptors on nasal chemosensory neurons to trigger olfactory bulb-to-brain neurocircuits without requiring blood absorption or brain uptake.
  • The company aims to treat social anxiety disorder, major depressive disorder, vasomotor symptoms associated with menopause, & premenstrual dysphoric disorder.
  • Investor inquiries can be directed to Mark A. McPartland at markmcp@vistagen.com, while media inquiries go to Michelle P. Wellington at mwellington@vistagen.com.